CRVS
insider transactionsCorvus Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 90 days, totalling $333.7K.
Net shares · 90d
+21.8K
28.6K buy · 6.9K sell
Net value · 90d
-$401.4K
$333.7K in · $735.0K out
Sentiment · 90d
Net buying
31% buying · 69% selling
Open-market trades · 90d
4
28.6K buy · 6.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
15.0K sh
Own New
-
Buy·P
Director
$250.2K
21.7K sh · $11.53
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director, 10% Owner
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
20.6K sh
Own New
-
Grant·A
Director
$0
5.1K sh
Own +31%
-
Sell·S
Director
$735.0K
6.9K sh · $106.90
Own -70%
-
Buy·P
President and CEO
$23.2K
1.9K sh · $12.01
Own +0%
-
Buy·P
President and CEO
$60.2K
5.0K sh · $12.05
Own +0%
-
Grant·A
Director
$0
30.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | David Scott Moore | Grant A | 15.0K | $0 |
| Jun 11, 2026 | David Scott Moore | Buy P | 21.7K | $250.2K |
| Jun 11, 2026 | Linda Grais | Grant A | 15.0K | $0 |
| Jun 11, 2026 | Peter A. Thompson | Grant A | 15.0K | $0 |
| Jun 11, 2026 | Richard Van Den Broek | Grant A | 15.0K | $0 |
| Jun 11, 2026 | Ian T Clark | Grant A | 15.0K | $0 |
| May 27, 2026 | Ian T Clark | Grant A | 20.6K | $0 |
| May 27, 2026 | Ian T Clark | Grant A | 5.1K | $0 |
| May 20, 2026 | Ian T Clark | Sell S | 6.9K | $735.0K |
| May 18, 2026 | Richard A Miller MD KEY | Buy P | 1.9K | $23.2K |
| May 18, 2026 | Richard A Miller MD KEY | Buy P | 5.0K | $60.2K |
| Apr 23, 2026 | Andrew C. Chan | Grant A | 30.0K | $0 |
About CRVS insider trading
This page tracks insider transactions for Corvus Pharmaceuticals, Inc. (CRVS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.